References
- Lew DP, Waldvogel FA. Osteomyelitis. N Eng J Med 1997; 336 (14): 999–1007.
- Dlovisio JR, Juneau J, Baumgarten K, Kateiva J. Clin Infect Dis 2000; 30: 639–642.
- McCue JD. Oral antibiotics: practical prescribing rules for practitioners. Geriatrics 1992; 47: 59-60,65–66.
- Paladino JA. Pharmacoeconomics of antimicrobial ther-apy. Am J Health Syst Pharm. 1999; 56: S25–28.
- Parodi S, Rhew DC, Goetz MB. Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infec- tions. J Managed Care Pharm 2003; 9: 317–326
- Zhiming J, Willke RJ, Rittenhouse BE, Glick HA. Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methcillin-resistant Staphylococcus species infections. Pharmacotherapy 2002; 22: 455–545
- Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid follow-ing multiple oral doses. Antimicrobl Agents Chemother 2001; 45 (6): 1843–1846.
- Clemett D, Markham A. Linezolid. Drugs 2000; 59 (4): 815-827.
- ZyvoxV prescribing information. Pharmacia & Upjohn Company, Kalamazoo, MI. November 2003.
- Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tis-sues. J Antimicrob Chemother 2002; 50 (5): 747–750.
- Stevens DL, Herr D, Lampiris H, Hunt JL, Batts D, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34 (11): 1481–1490.
- Wunderink RG, Rello J, Cammarata SK, Cross-Dabrera RV, Kollef MH. Linezolid versus vancomycin. Analysis of two double-blinded studies of patients with methicillin-resistant Staphylococcus aureus nosocominal pneumonia. Chest 2003; 124 (5): 1789-1797.
- Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004; 32 (1): 8–14.
- Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004; 79 (9): 1137–1144.
- Guglielmo BJ, Luber AD, Paletta D, Jacobs RA. Ceftriaxone therapy for Staphylococcus osteomyelitis: a review. Clin Infect Dis 2000; 30 (1): 205–207.
- Sax H, Lew D. Osteomyelitis. Curr Infect Dis Rep 1999; 1: 261–266.
- Nasraway SA, Shorr AF, Kuter DJ, O'Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37 (12): 1609–1616.
- Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL. Similar hematologic effects of long-term linezolid and van-comycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 2004; 38 (8): 1058–64.